The number of incidences of road accidents and aging population in major regions of world is increasing. The estimated number of road accident incidences collectively in North America, APAC and in Europe in 2014 was 7.7 million. While aging population in these three regions was 367 million in 2014. Both factors increase chances for musculoskeletal injuries. Using traditional methods to treat chronic complex musculoskeletal injuries that are slow to heal pose challenges to physicians.
In natural bone healing process, following an injury to bone, platelets are activated and degranulate. On Degranulation of platelets releases a number of critical growth factors such as PDGF in its vicinity (area of injury). The principal actions of PDGF are chemotaxis, mitogenesis, and promotion of angiogenesis which start the cascade of bone healing process. Collectively these actions ensure an adequate number of appropriate cell types are available to drive all phases of the bone healing process.
Orthobiologics is a relatively newer field that offers exciting new possibilities to promote and accelerate bone and soft tissue healing by application of naturally found materials from biological sources (for example, cell-based therapies).
Platelet-rich plasma (PRP) is an orthobiologic that has recently earned popularity as an adjuvant treatment for musculoskeletal injuries. It enhances bone and soft-tissue healing by placing supra-physiological concentrations of autologous platelets at the site of tissue damage. Usually the concentration of platelets in PRP is four to eight times than normal blood platelet concentration.
PRP is an effective treatment to treat various orthopedic diseases, sports injuries, neurological diseases and cardiothoracic diseases. PRP therapy also shows its application in cosmetic industry as dermal fillers.
The relative ease of preparation, applicability in the clinical setting, favorable safety profile and possible beneficial outcome make PRP a promising therapeutic approach for future regenerative treatments. Presently, factors such as, increased number of people suffering orthopedic injuries, growing PRP awareness, new devices and applications for PRP, and growing geriatric population are driving this market.
The global plasma-rich plasma market has been segmented on the basis of type, origin, application, and geography. On the basis of types market is further segmented into pure-PRP, leukocyte-rich PRP, and pure PRF/leukocyte-rich PRF. On the basis of origin, the market has been segmented into autologous PRP, homologus PRP and allogenic PRP. By applications, the global PRP market has been further segmented as neurosurgery, cosmetic surgery, orthopedic surgery, general surgery and others (cardiothoracic surgery, urology, periodontal surgery and oral and maxillofacial surgery). Report includes segmentation of global PRP market on the basis of geography as well. By geography, market is segmented into four regions named as North America, Europe, Asia-Pacific (APAC), and Rest of World (RoW).
The autologous PRP segment was largest segment of global PRP market in 2013, but the scenario is not expected to be remained same by 2019. High concentration of growth factors and less healing time made allogenic PRP as product of choice. Allogenic PRP segment is growing at highest CAGR and expected to be largest segment of Global PRP market by 2019.
Increased cosmetic and orthopedic procedures, key players domiciled in the region, and strong awareness about PRP therapy in North America, made it largest market accounted for more than 50% of global market in 2013. Asia- Pacific is most promising and fastest growing market. Medical tourism, wide presence of local players, high geriatric population growing PRP therapy awareness are the major factors that are driving the APAC market.
The major players of this market are AdiStem Ltd., Arteriocyte Medical Systems, Inc., Arthrex, Inc., Biomet, Inc., Cesca Therapeutics, Inc., DePuy Synthes, Inc., Dr. PRP America LLC., EmCyte Corporation, Exactech, Inc., Harvest Technologies Corp., Nuo Therapeutics, Inc., Regen Lab SA, and Stryker Corporation.
